Bristol-Myers Squibb is a global biopharmaceutical company focused on discovering, developing, and delivering innovative medicines for patients with serious diseases. 

Pharmaceutical

Bristol-Myers Squibb

Cari Gallman, chief compliance and ethics officer, is responsible for reinforcing the company’s strong culture of ethics and integrity; she champions efforts that ensure our operations are conducted in compliance with ethical business practices, our Principles of Integrity, and laws and regulations in the global markets in which we operate. In addition to reporting to the General Counsel and CEO, Cari also reports to the Chair of the Audit Committee of the Board of Directors.

“Our deep and unwavering commitment to ethics and integrity provides the foundation for everything we do. It guides how we interact with our colleagues and external partners, as well as the work we do on behalf of our patients and communities around the world,” she says.

Cari has 15 years of combined experience in pharmaceutical law and compliance. She began her legal career in private practice representing pharmaceutical and medical device manufacturers in government enforcement and regulatory matters. In her practice, she regularly advised companies on how to design and implement robust compliance policies to meet business objectives as well as legal needs. She joined the company in 2015 and assumed positions of increasing responsibility, including as head of the legal team supporting the Global Oncology Commercialization and Development organizations. 

She earned a bachelor’s degree in political theory from Princeton University and a JD from Harvard Law School.

Cari Gallman

Murdo Gordon is currently the EVP & Chief Commercial Officer at [Bristol-Myers Squibb](/org/bristol-myers-squibb). Murdo has been in this role since October 2018. Prior to this, they were the Director at Robert Wood Johnson University Hospital from January 2012 to October 2018. Prior to that, they were the Chief Commercial Officer at [Bristol-Myers Squibb](/org/bristol-myers-squibb) from September 2006 to August 2018. Murdo has also held the position of Executive Director Plavix Marketing at [Bristol-Myers Squibb](/org/bristol-myers-squibb) from January 1999 to December 2006.

Murdo Gordon has a degree in cell and molecular biology from [Concordia University](/org/concordia-university), a DEC in health science from CEGEP - John Abbott College, and a GM Prog from INSEAD.

They work with Kimberly Lounds Foster - SVP, Global Supply Chain, Samit Hirawat - EVP & Chief Medical Officer, Global Drug Development, and Elizabeth Mily - EVP, Strategy & Business Development. Murdo Gordon reports to Giovanni Caforio, Chairman & CEO.

Murdo Gordon

As chief of staff, Wendy Short Bartie supports the office of the chief executive officer and plays a strategic role in driving enterprise initiatives. 

Wendy has more than 20 years’ experience in the pharmaceutical industry with a history of leading teams to achieve global commercial excellence in a range of commercial roles with increasing responsibility in sales, business analytics and marketing.

She joined Bristol Myers Squibb in 2021 and was previously senior vice president and head of U.S. Oncology. In this capacity, Wendy was responsible for leading strategy and operations for the solid tumor program in the U.S. Prior to joining Bristol Myers Squibb, Wendy was vice president and head of Commercial Operations for U.S. Oncology at Merck.

“My career journey has taken many turns, but my path has always been clear – the commitment to help people – first as a public defender, and then as a pharmaceutical industry professional,” she says. “My goal is to continue to act as a voice for those with unmet needs and unequal access.”

Prior to her career in pharma, Wendy was a Public Defender in Washington, DC, and Bronx, New York.

Wendy received her bachelor’s degree from Clark Atlanta University and her juris doctor (JD) from Loyola University Chicago, School of Law.

Wendy Short Bartie

Estelle Vester-Blokland has over 20 years of experience in the pharmaceutical industry. Estelle is currently the SVP of Global Medical Affairs at [Bristol-Myers Squibb](/org/bristol-myers-squibb). Prior to their current position, they served as the Head of Personalized Health Care and Medical Access at F. Hoffmann-La Roche from March 2017 to December 2018. From June 2013 to February 2017, they were the Life Cycle Leader for Alzheimer's Disease at Roche. Estelle has also held positions as the European Disease Strategy Lead for Oncology at [Bristol-Myers Squibb](/org/bristol-myers-squibb) in Paris, France from November 2011 to June 2013 and the Executive Director of Medical Affairs Neuroscience US from March 2007 to January 2009.

Estelle Vester-Blokland is a medical doctor who studied at [Utrecht University](/org/utrecht-university).

Estelle Vester-Blokland reports to Chris Boerner, EVP & Chief Commercialization Officer.

Estelle Vester-Blokland

Sandra Leung is the EVP & General Counsel at [Bristol-Myers Squibb](/org/bristol-myers-squibb).

Prior to joining [Bristol-Myers Squibb](/org/bristol-myers-squibb), Sandra served as an Assistant District Attorney for the New York County District Attorney from January 1984 to December 1992.

Sandra Leung received their Bachelor of Arts in Political Science and Government from [Tufts University](/org/tufts-university). Sandra then attended Boston College Law School and received their Juris Doctor.

Their manager is Giovanni Caforio, Chairman & CEO. Some of their coworkers include Ann M. Powell - EVP & CHRO, Samit Hirawat - EVP & Chief Medical Officer, Global Drug Development, and Greg Meyers - EVP, Chief Digital & Technology Officer.

Sandra Leung

Karin Shanahan oversees worldwide product development, manufacturing and supply for Bristol Myers Squibb as executive vice president, Global Product Development & Supply (GPS). GPS develops and produces active ingredients and drug products and delivers the company’s medicines throughout the world. The GPS team achieves this mission through a relentless focus on innovation, quality, safety and agility.

“I’m excited to return to Bristol Myers Squibb, where I began my career in the pharmaceutical industry. Though I’ve worn many hats in the industry since then, I was drawn back to Bristol Myers Squibb because of its unwavering dedication to quality and delivering innovative medicines to patients in need,” says Karin. “I am honored to help lead the integral GPS team as we navigate an everchanging landscape.”

Karin began her career in the pharmaceutical industry at Bristol Myers Squibb in corporate procurement, global supply chain, and global quality. Karin moved into manufacturing operations, leading two manufacturing sites in Billerica, MA, and Latina, Italy. After almost 14 years with Bristol Myers Squibb, Karin joined Becton-Dickenson as a leader of global operations,  followed by Catalent Pharmaceuticals where she led global Biologics operations. In 2013, Karin joined Teva Pharmaceuticals as senior vice president and chief operating officer of global operations, where she led global Manufacturing Science & Technology (MS&T) and Network Strategy and a network of 25 sites across Europe and the Americas. Most recently, Karin served as senior vice president of Global Biologics & Sterile Operations at [Merck](/org/merck).

 

Karin Shanahan

David Elkins is the Chief Financial Officer responsible for Global Business Operations, which includes Business Insights and Analytics, Global Finance and Global Procurement.

David joined Celgene in July 2018 after several years at [Johnson & Johnson](/org/johnson-johnson) (J&J), where he served as Chief Financial Officer for that company’s Consumer Products, Medical Devices and Corporate Functions. Prior to J&J, his experiences include EVP & Chief Financial Officer of Becton, Dickinson and Company, a public global medical technology company. From 1995 to 2008, he held roles of increasing responsibility at [AstraZeneca](/org/astrazeneca), and he began his career in finance at the Boeing Company in 1991. 

David Elkins

Rupert Vessey leads Research and Early Development, overseeing the advancement of promising programs, technologies and assets across all therapeutic areas, from discovery through proof-of-concept. He also works closely with Business Development to identify external sources of innovation.

Rupert joined BMS from Celgene, where he served as President of the company’s Research and Early Development organization. Prior to joining Celgene in 2015, Rupert spent ten years at [Merck](/org/merck), where he was responsible for numerous drug development programs and held leadership roles in the company’s Early Development, Discovery Sciences, Drug Discovery and Informatics groups, as well as its respiratory and immunology franchise. Prior to his time at [Merck](/org/merck), he spent five years at GlaxoSmithKline involved in drug discovery, experimental medicine and early clinical development of therapeutics for respiratory and immune diseases. 

Rupert Vessey

Michael W. Bonney is currently the Executive Chair of the Board of Kaleido Biosciences, Inc., having served as Chief Executive Officer and Chairman from June 2017 to August 2018. From January to July 2016, he was a Partner of Third Rock Ventures, LLC. Previously, Mr. Bonney served as Chief Executive Officer and a member of the Board of Directors of Cubist Pharmaceuticals Inc. (which was acquired by Merck & Co., Inc. in January 2015) from June 2003 until December 2014. Prior to Cubist, he was Vice President, Sales and Marketing at [Biogen](/org/biogen), Inc. Prior to joining [Biogen](/org/biogen), Mr. Bonney spent eleven years at Zeneca Pharmaceuticals, in a range of commercial, operating and strategic roles, ending his career there as National Business Director. He chairs the Board of Directors of Alnylam Pharmaceuticals, Inc. and [Magenta Therapeutics](/org/magenta-therapeutics). Mr. Bonney also currently serves as a member of the Board of Directors of Sarepta Therapeutics Inc. and Syros Pharmaceuticals. He previously served as a member of the Board of Directors of Global Blood Therapeutics, Inc. and NPS Pharmaceuticals, Inc. Mr. Bonney currently serves on the Celgene Board of Directors, where he is a member of the Executive Committee as well as the Nominating, Governance and Compliance Committees. He received a B.A. in Economics from [Bates College](/org/bates-college) and chaired its Board of Trustees from 2012 to June 2019. Mr. Bonney has committed to complying with the company’s policy that directors should not serve on more than four public company boards by the end of the first quarter of 2020.

Michael Bonney

Phyllis Yale is currently an advisory partner with [Bain & Company](/org/bain) where she has been a leader in building Bain's healthcare practice over the last 30 years. Ms. Yale has served in a number of leadership roles at Bain and now devotes her time to client work. She is currently Chair of the Board of Blue Cross Blue Shield of Massachusetts and serves on the Board of DaVita, Inc. Previously, Ms. Yale served on the boards of Kindred Healthcare, Inc., National Surgical Hospitals, Inc., Value Options, Pediatric Services of America and NeighborCare, Inc. She also has served on the non-profit boards of [The Trustees of Reservations](/org/trustees-of-reservations), [The Bridgespan Group](/org/the-bridgespan-group) and Cradles to Crayons; as well as a number of advisory boards, including the Advisory Board for the HBS Healthcare Initiative, and the Executive Council for the Department of Health Policy and Management of the Harvard Chan School of Public Health. Ms. Yale earned an MBA from [Harvard Business School](/org/harvard-business-school) with honors and is a graduate of Harvard and Radcliffe Colleges, where she received a Bachelor of Arts degree in Economics magna cum laude.

Phyllis Yale

Rick Szymialis

Angela Garcia

With more than 35 years in the financial industry, Theodore (Ted) Samuels, age 64, brings to the Board extensive business and operational experience, particularly with respect to economics, capital markets and investment decision making. Mr. Samuels is the former President of Capital Guardian Trust Company from 2010 until 2016 and a former global equity portfolio manager at Capital Group, one of the most prominent investment management organizations in the world from 1990 until 2016.  While at Capital Group he served on numerous management and investment committees, with an eye towards long-term shareholder value creation.  He also serves as Co-Chair of Tuft’s President’s Council and the Harvard West Coast Council.

 

Mr. Samuels currently serves as a Director at Perrigo Company, PLC, and [Stamps.com](/org/stamps-com).

Theodore R. Samuels

Dr. Bhatt has served as the executive director of interventional cardiovascular programs at Brigham and Women’s Hospital since 2013. He is also a professor of medicine at Harvard Medical School.
 
Dr. Bhatt offers to the Board more than 20 years of research experience in acute coronary syndromes, preventive cardiology, and advanced techniques in cardiac, cerebral, and peripheral intervention. He has served as the principal or co-principal investigator for cardiovascular clinical trials focused on interventional cardiology, anti-thrombotic therapy, lipid-lowering therapy, heart failure, obesity, and diabetes, among other areas. 

Prior to his current position, Dr. Bhatt served as chief of cardiology at VA Boston Healthcare from 2008-2013. From 2001-2008, Dr. Bhatt held a number of roles of increasing responsibility at the Cleveland Clinic in Cleveland, Ohio. In addition to being an attending physician, he served as an associate director of the Cleveland Clinic Cardiovascular Coordinating Center, director of the interventional cardiology fellowship, as well as the associate director of the cardiovascular medicine fellowship. 

Deepak L. Bhatt

Ms. Price, age 58, has more than 30 years of financial and operational experience.  Most recently, she served as Executive Vice President (EVP) and Chief Financial Officer (CFO) of Macy’s Inc. until May 2020.  She currently remains an advisor to the renowned retailer.  
 
Prior to that, she was a full-time Senior Lecturer for [Harvard Business School](/org/harvard-business-school) in the Accounting and Management Unit from 2014-2018.  Before that, Ms. Price also served as EVP and CFO for Ahold USA, Controller and Chief Accounting Office (CAO) of CVS Caremark Corporation, and in senior leadership positions at [JPMorgan Chase](/org/jpmorgan-chase), [Prudential Financial](/org/prudential-financial), [Diageo](/org/diageo), and Kraft Foods.  A certified Public Accountant (CPA), she began her career at Arthur Andersen & Co.  
 
Ms. Price currently serves on the Boards of Directors of Accenture plc and Western Digital Corp.  She previously served on the Board of Directors of Dollar General Corporation.  Ms. Price earned her M.B.A. degree from the University of Chicago and her B.S. degree in accountancy from [DePaul University](/org/depaul-university).

Paula A. Price

Kimberly Lounds Foster is Senior Vice President, Global Supply Chain at [Bristol-Myers Squibb](/org/bristol-myers-squibb), where she oversees the clinical and commercial supply chain. Bristol develops and manufactures products on multiple technology platforms, including small molecules, biologics and cell therapies. Kimberly joined Bristol through the Celgene acquisition in 2019 after leading Celgene’s Global Technical Operations organization. Prior to Celgene, Ms. Foster was Head of Global Supply Chain at [Novartis](/org/novartis)’ Cell & Gene Therapy unit, where she was responsible for building out the commercial and clinical autologous supply chain for KYMRIAHTM (tisagenlecleucel), the first FDA approved CAR T cell therapy. Ms. Foster held various positions at [Sandoz](/org/sandoz) a [Novartis](/org/novartis) company where she built the External Supply Operations functions for the Americas and managed [Sandoz](/org/sandoz) US supply chain for in-line products, new products launches and managed the warehouse and distributions network. Prior to [Sandoz](/org/sandoz), Ms. Foster held various roles of increasing responsibilities at Catalent Pharma Solutions, Baxter Healthcare, [Accenture](/org/accenture) and [Merck](/org/merck). Ms. Foster’s diverse experience includes business development, mergers & acquisitions, management consulting, strategic planning, process engineering and operational excellence. Ms. Foster holds an M.B.A from The Wharton School, [University of Pennsylvania](/org/university-of-pennsylvania) and a B.S. in Chemical Engineering from [Northwestern University](/org/northwestern-university).

Kimberly Lounds Foster

As Executive Vice President, Corporate Affairs, Michelle Weese oversees the company’s initiatives to protect, promote and enhance the Bristol Myers Squibb brand and reputation through strategic communications, government relations and policy, corporate social responsibility and patient advocacy.

Michelle joins BMS from the global food and beverage company [Danone](/org/danone), where she served for two years as General Secretary for North America and also led strategic corporate functions, including government and public affairs, communications, community affairs, scientific affairs and sustainable development for North America.

In 2009 she founded the private consulting firm, strat-igence, serving as its CEO and working with a range of clients from the biopharmaceutical and consumer packaged goods industries, including [Johnson & Johnson](/org/johnson-johnson), Church & Dwight, [PepsiCo](/org/pepsico) and [Unilever](/org/unilever), on issues such as crisis management, corporate affairs and corporate transformation. Prior to that, she held positions of increasing leadership responsibility in corporate affairs at Mars, Inc. including serving as Global Head of Communications. 

Michelle Weese

Dr. Hidalgo, age 53, has served as chief of the division of hematology and medical oncology at Weill Cornell Medicine and New York-Presbyterian/Weill Cornell Medical Center since 2019 and is responsible for leading clinical and translational research in hematology, vascular biology and oncology. He is also the E. Hugh Luckey distinguished professor of medicine and associate director for clinical services at the Sandra and Edward Meyer Cancer Center at Weill Cornell Medicine. 

Dr. Hidalgo brings to the Board more than 20 years of experience in translational and clinical research in anticancer drug development, with an emphasis in gastrointestinal cancers.  He has also led the early clinical development of new anticancer agents for pancreatic cancer among other solid tumor cancers.

Prior to his current position, Dr. Hidalgo served as chief of the division of hematology at Beth Israel Deaconess Medical Center in Boston and clinical director of the Rosenberg Clinical Cancer Center from 2015 to 2019. During this time, he was the Theodore W. and Evelyn G. Berenson Professor of Medicine at Harvard Medical School. Dr. Hidalgo also held leadership positions at the Spanish National Cancer Research Centre (CNIO) in Madrid and at the Kimmel Comprehensive Cancer Center, where he was director of gastrointestinal oncology program.

Dr. Hidalgo is a paid Scientific Advisory Board member for [Agenus](/org/agenus) (NASDAQ: AGEN), from which he plans to step down in connection with his election to Bristol Myers Squibb’s Board.

Manuel Hidalgo Medina

Greg Meyers leads the Information Technology organization, positioning the company for success in the rapidly evolving digital age. His priority is to accelerate the company’s strategy through digital technology and data enablement, adopting new approaches to digital health, and fostering long-term partnerships with external technology companies and digital innovators. He is also responsible for ensuring we have both secure and reliable IT infrastructure and the platforms necessary to drive our ambitious innovation agenda.

Greg is an accomplished senior executive with extensive experience as an agent of change and during his career, he has held profit & loss roles, led digital transformations, managed complex cybersecurity threats in diverse geopolitical environments, and is recognized as a thought leader and futurist in several industries.

Greg holds a bachelor’s degree in marketing from Rutgers University with a minor in computer science, and a master’s degree in business administration from Temple University.

Greg Meyers

As vice president and chief diversity and inclusion officer, Pamela Fisher drives the global diversity and inclusion (GD&I) business strategy and operating plans, connects the GD&I commitments to business performance, innovation and patient outcomes, and continues to strengthen and shape the diverse and inclusive culture. She provides leadership to the Global Diversity Inclusion Council and People & Business Resource Groups.

In addition to serving as a member of the leadership team, Pam reports to the chief human resources officer Ann Powell.

Pamela Fisher

Mr. Rice, age 55, served as Executive Vice President (EVP) of [CVS Health](/org/cvs-health) and President of its pharmacy benefits management (PBM) business, CVS Caremark, where he led the PBM business from March 2018 to February 2020.  
 
Prior to that, he served as the EVP of global services and CFO for [Eli Lilly](/org/eli-lilly) and Company from 2006 to 2017.  During his 27-year tenure at [Eli Lilly](/org/eli-lilly), Mr. Rice was instrumental in helping to drive the company’s innovation strategy and held numerous roles in finance and operations.  
 
He is currently a member of [The Walt Disney Company](/org/disney)’s Board of Directors and previously served on the Board of Directors of Target Corporation.  Mr. Rice holds an M.B.A. degree from [Indiana University](/org/indiana-university) and a B.S. degree in electrical engineering from [Kettering University](/org/kettering-university).

Derica W. Rice

Senior Group Leader, [The Francis Crick Institute](/org/the-francis-crick-institute) and Chief Scientist, [Cancer Research UK](/org/cancer-research-uk)

Karen H. Vousden

Gerald L. Storch

President and Chief Executive Officer of Integra LifeSciences Holdings Corporation

Peter J. Arduini

Ann M. Powell

Samit Hirawat

Tim Power

Dr. Caforio has been our Chief Executive Officer since May 2015. He was our Chief Executive Officer Designate from January to May 2015, our Chief Operating Officer from June 2014 to May 2015, and he served as Executive Vice President and Chief Commercial Officer from November 2013 to June 2014.

From October 2011 to November 2013, he served as President, U.S. He held the position of Senior Vice President, Global Commercialization and Immunology from May 2010 to October 2011. Prior to that, he served as Senior Vice President, Oncology, U.S. and Global Commercialization from March 2009 to May 2010.

From January 2007 to March 2009 he served as Senior Vice President, U.S. Oncology and from May 2004 to January 2007, he served as Senior Vice President, European Marketing and Brand Commercialization.

Dr. Caforio is a member of the Board of Trustees of Hun School of Princeton and a member of the Business Roundtable, CEO Roundtable on Cancer and the Pharmaceutical Research and Manufacturers of America (PhRMA) and The Prium.

Giovanni Caforio

Chris Boerner

Julia A. Haller, M.D., has served since 2007 as Ophthalmologist-in-Chief of Wills Eye Hospital in Philadelphia, where she holds the William Tasman, M.D. Endowed Chair. She is Professor and Chair of the Department of Ophthalmology at Sidney Kimmel Medical College at Thomas Jefferson University and Thomas Jefferson University Hospitals. A magna cum laude graduate of Princeton, Dr. Haller received her M.D. degree from Harvard Medical School. She served as the first female Chief Resident at the Wilmer Eye Institute at Johns Hopkins and later joined the Johns Hopkins faculty, where she held the Katharine Graham Chair in Ophthalmology. One of the world's most renowned retina surgeons, Dr. Haller has been closely involved in the early stage development of many new vision therapies and is a past member of the Board of Trustees of [Princeton University](/org/princeton), and a consultant at Children’s Hospital of Philadelphia. She currently serves on the Celgene Board of Directors, where she is a member of the Audit Committee.

Julia A. Haller

Elizabeth is an accomplished leader in investment banking and health care M&A, and I look forward to the important role she will play in sourcing external innovation to drive our vision of transforming patients’ lives through science

Bristol-Myers Squibb

Org chart

Teams

CEO and Executive Team

Leadership Team

Board of Directors

Discover similar companies